Transfusion associated circulatory overload
Methodology & AI Transparency ⓘ
Transfusion associated circulatory overload Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as E87.71, Transfusion associated circulatory overload falls under Kidney & Renal management, where spot urine albumin-to-creatinine in Transfusion associated circulatory overload (E87.71: ratio) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Transfusion associated circulatory overload uses ICD-10 E87.71 across Kidney & Renal specialty care.
- 3 Typical cash cost range: Clinicians assessing Transfusion associated circulatory overload focus on impaired nephron solute/acid-base in Transfusion associated circulatory overload (E87.71: clearance) and targeted history.
- 4 Top reported side effects / signs: Key Kidney & Renal biomarkers for Transfusion associated circulatory overload (E87.71): Urine Albumin-to-Creatinine Ratio in Transfusion associated circulatory overload (E87.71: (uACR)) & Serum Potassium, Bicarbonate in Transfusion associated circulatory overload (E87.71: & Phosphorus) (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.71)).
Ask our AI Specialists anything about Transfusion associated circulatory overload
What Is Transfusion associated circulatory overload?
Designated in federal medical registries as E87.71, Transfusion associated circulatory overload falls under Kidney & Renal management, where spot urine albumin-to-creatinine in Transfusion associated circulatory overload (E87.71: ratio) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Transfusion associated circulatory overload (E87.71) alters kidney & renal homeostasis through impaired nephron solute/acid-base in Transfusion associated circulatory overload (E87.71: clearance); clinical remission targets Serum Potassium, Bicarbonate in Transfusion associated circulatory overload (E87.71: & Phosphorus) within K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.71).
Common Symptoms & Clinical Signs
- • Presentation of Transfusion associated circulatory overload (E87.71): changes in urine in Transfusion associated circulatory overload (E87.71: output volume, nocturnal)
- • Secondary Transfusion associated circulatory overload clinical sign: asymptomatic decline in in Transfusion associated circulatory overload (E87.71: eGFR or persistent)
- • Symptom flares in Transfusion associated circulatory overload correlating with Urine Albumin-to-Creatinine Ratio in Transfusion associated circulatory overload (E87.71: (uACR)) deviation outside < 15 mg/g (< 30 mg/g normal) (E87.71)
- • Functional kidney & renal impact requiring spot urine albumin-to-creatinine in Transfusion associated circulatory overload (E87.71: ratio) evaluation (E87.71)
Transfusion associated circulatory overload Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E87.71 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Transfusion associated circulatory overload (E87.71: (uACR)) | < 15 mg/g (< 30 mg/g normal) (E87.71) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Transfusion associated circulatory overload (E87.71: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (E87.71) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Transfusion associated circulatory overload (E87.71: Cystatin C)) | >= 90 mL/min/1.73m2 (E87.71) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Transfusion associated circulatory overload
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Aminocaproic Acid Amicar • RxCUI 197351 | Antifibrinolytic Agent | 84% | $2.4779 | $ 45.68 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Transfusion associated circulatory overload)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines:: What a 300-Participant Study Found CKDB-501A is a safe and effective alternative to existing botulinum toxin products for treating moderate-to-severe glabellar lines, offering benefits of improved biocompatibility and reduced risk of allergic reactions. Journal of cosmetic dermatology • 2025-07-15 • Phase III Randomized Trial | N = 300 | 93/100 | PMID 40586136 ↗ |
| Can This Approach Help? Inside the Latest Research on Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for The results of this study showed that the risk of RCC returning or death was not changed with adjuvant nivolumab plus ipilimumab treatment compared with placebo. Targeted oncology • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37659025 ↗ |
| Can This Approach Help? Inside the Latest Research on Eltrombopag during induction chemotherapy in older patients with newly diagnosed This study failed to demonstrate a survival advantage after eltrombopag addition, at variance with previous reports, but shows that initiating eltrombopag after chemotherapy washout is feasible and safe, and resulted in a... Cancer • 2026-11-01 • Randomized Controlled Trial | N = 110 | 88/100 | PMID 42963911 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Luspatercept offers rapid and durable benefits by improving anemia-related symptoms and quality of life in patients with NTDT. European journal of haematology • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41857682 ↗ |
| New Insights on Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in: What a 756-Participant Study Found These findings indicate no evidence of difference in incidence of red blood cell transfusion for a titration-dose strategy versus a fixed-dose strategy for darbepoetin. Journal of the American Society of Nephrology : JASN • 2021-02-15 • Phase III Randomized Trial | N = 756 | 87/100 | PMID 33288629 ↗ |
Transfusion associated circulatory overload Patient Community & “People Like Me” Threads
Filter Transfusion associated circulatory overload community threads and patient logs by age, biological sex, dosage, and treatment duration.